Skip to main content
OpenTrials
Completed

NCT Number: NCT04396119

Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hodgkin Lymphoma Hemic and Lymphatic Diseases Hodgkin Disease Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom

About this study

Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors' understanding of cancer screening as a concept and the benefits of screening and early detection Explore survivors' level of awareness of and attitudes towards their lung cancer risk Explore survivors' views on the barriers and motivating factors that would impact their decision to attend a lung cancer screening test

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Details held in the ADAPT database at The Christie NHS Foundation trust
  • Responded to most recent ADAPT study questionnaire (April - August 2019)
  • Aged 18-80
  • Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
  • Able to provide informed consent
  • Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or alkylating agent containing chemotherapy.

Exclusion criteria

  • Previous or current diagnosis of lung cancer
  • Stated within 2019 health questionnaire that they did not wish to be contacted
  • Have participated in lung cancer screening through the Manchester Lung Health Checks

Treatment and study plan

Primary outcomes

  1. Explore survivors' attitudes towards lung cancer and lung cancer screening

    Time frame: 6 months

    Semi-structured interviews

Sponsors and collaborators

Lead sponsor

The Christie NHS Foundation Trust

Other

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
May 20, 2020
Registry last updated
Sep 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.